Doxyveto – 50 S Powder for oral solution

Nazione: Arabia Saudita

Lingua: inglese

Fonte: SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

Compra

Scheda tecnica Scheda tecnica (SPC)
12-05-2024

Principio attivo:

Doxycycline hyclate

Commercializzato da:

VMD-nv, Belgium

Codice ATC:

QJ01AA02

INN (Nome Internazionale):

Doxycycline hyclate

Dosaggio:

500 mg/g

Forma farmaceutica:

Powder for oral solution

Via di somministrazione:

Oral use

Confezione:

1 Jar

Classe:

Generic

Tipo di ricetta:

Uncontrolled

Prodotto da:

, 1843

Dettagli prodotto:

Agent: Fursan Al-Ahram Trading Est.; Storage conditions: g

Stato dell'autorizzazione:

Marketed; Valid

Data dell'autorizzazione:

0000-00-00

Scheda tecnica

                                DOXYVETO
-
50 S
SOLUBLE POWDER
CONTAINS PER GRAM POWDER: 577 mg doxycycline hyclate equivalent to 500
mg doxycycline
with
DOXYVETO-50 S
breathe free
3
3
Highest bioavailability of all tetracyclines
3
3
Broad spectrum, including Mycoplasma
3
3
Even stable at higher temperatures
INDICATIONS
Treatment of infections of the respiratory and gastro-
intestinal tract caused by micro-organisms sensitive to
doxycycline.
•
CHICKENS:
-
Respiratory infections caused by _Mycoplasma spp, _
_Escherichia coli, Haemophilus paragallinarum_ and
_Bordetella avium_;
-
Enteritis caused by _Clostridium perfringens _
and _Clostridium colinum._
•
CALVES:
-
Bronchopneumonia and pleuropneumonia
caused by _Pasteurella spp, Streptococcus spp, _
_Arcanobacterium pyogenes, Histophilus somni _
and_ Mycoplasma spp._
•
PIGS:
-
Atrophic rhinitis caused by _Pasteurella multocida_
and _Bordetella bronchiseptica; _Bronchopneumonia
caused by _Pasteurella multocida, Streptococcus _
_suis _and _Mycoplasma hyorhinis;_
-
Pleuropneumonia caused by _Actinobacillus _
_pleuropneumoniae. _
CONTRAINDICATIONS
Do not use in case of hypersensitivity to tetracyclines
or to any of the excipients.
PHARMACODYNAMIC PROPERTIES
Doxycycline is a broad spectrum antibiotic. It inhibits
bacterial protein synthesis intracellularly by binding to the
30S ribosomal subunits. The entry of aminoacetyl-tRNA
to the acceptor site on the mRNA ribosome complex is
blocked in this manner, whereby coupling of the amino
acids to the forming peptide chain is prevented. Doxycy-
cline inhibits bacteria, Mycoplasmata, Chlamydia, Rick-
ettsia and certain protozoa.
PHARMACOKINETIC PROPERTIES
Doxyveto-50 S is quickly and almost completely absorbed
from the intestine. Presence of food in the intestine has no
effect on the actual absorption of the veterinary medicine.
The distribution in the body and the penetration is good.
Following
absorption,
tetracyclines
are
hardly
metab-
olized.
Unlike
other
tetracyclines
is
the
excretion
of
Doxyveto-50 S mainly in the faeces and not in the kidneys,
mak
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Scheda tecnica Scheda tecnica francese 12-05-2024

Cerca alert relativi a questo prodotto